Suven Life Sciences Limited, a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, announced that it has successfully completed 100% patient enrollment for its Phase-2b clinical trial of Ropanicant, a nicotinic a4á2 receptor antagonist being evaluated for Major Depressive Disorder (MDD). The company achieved this milestone over two months ahead of schedule, with the study being conducted entirely in the United States.

The Phase-2b trial is a randomized, double-blind, placebo-controlled study involving approximately 195 patients across 35 US sites, with a treatment duration of six weeks. It aims to assess the efficacy and safety of Ropanicant in improving symptoms of depression, measured using the Montgomery-sberg Depression Rating Scale (MADRS). Suven reported that the trial reached full enrollment in less than six months since initiation, highlighting strong interest and participation from both investigators and patients. Ongoing safety monitoring has shown no significant concerns so far.

Suven expects to announce topline efficacy and safety results by May 2026.

Expressing gratitude for the rapid progress, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said the milestone reflects the dedication of patients, caregivers, investigators, and the clinical development team. He added that the company is committed to advancing Ropanicant as a potential new therapeutic option for individuals with MDD.

Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences, noted that strong patient and physician interest helped achieve full enrollment within six months of study initiation. He said that if successful, Ropanicant could significantly impact the treatment landscape for MDD, and the company looks forward to sharing the trial results in 2026.